Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
5 Jun, 20:00
NYSE NYSE
$
1,131. 42
+6.15
+0.5465%
$
1.02T Market Cap
104.2 P/E Ratio
0.05% Div Yield
4.08M Volume
6.64 Eps
$ 1,125.27
Previous Close
Add Transaction
Day Range
1,131.03 1,166.29
Year Range
623.78 1,166.29
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.

Zacks | 1 year ago
2 No-Brainer Dividend Growth Stocks to Buy Right Now

2 No-Brainer Dividend Growth Stocks to Buy Right Now

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

Fool | 1 year ago
LLY Stock Rises on Congressional Budget Office Report

LLY Stock Rises on Congressional Budget Office Report

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.

Gurufocus | 1 year ago
Why Eli Lilly Was Such a Healthy Stock Today

Why Eli Lilly Was Such a Healthy Stock Today

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.

Fool | 1 year ago
LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug

LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug

The Outsourcing Facilities Association, representing companies producing generic versions of Eli Lilly's (LLY, Financial) weight loss drug, has filed a lawsuit against the U.S. Food and Drug Administration (FDA) in a Texas federal court. The group claims that the FDA's decision to remove Eli Lilly's drug from the shortage list was "arbitrary, capricious, and unlawful.

Gurufocus | 1 year ago
Billion-Dollar News for Eli Lilly Stock Investors

Billion-Dollar News for Eli Lilly Stock Investors

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Fool | 1 year ago
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list

Compounding group sues FDA for removing Lilly's weight loss drug from shortage list

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly's blockbuster weight loss and diabetes drugs from its shortage list last week, a move expected to curtail compounding facilities' ability to sell their own versions of the drugs.

Reuters | 1 year ago
5 Large Drug Stocks to Watch From a Thriving Industry

5 Large Drug Stocks to Watch From a Thriving Industry

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

Zacks | 1 year ago
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.

Zacks | 1 year ago
The Big 3: LLY, CVX, RBLX

The Big 3: LLY, CVX, RBLX

Today's Big 3 dives into medical, energy and digital entertainment names. @ProsperTradingAcademy's Mike Shorr joins Rick Ducat and Nicole Petallides to break down the technical trends in Eli Lilly (LLY), Chevron (CVX), and Roblox (RBLX).

Youtube | 1 year ago
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.

Zacks | 1 year ago
LLY Outlook Crucial After Mounjaro, Zepbound Shortage Ends

LLY Outlook Crucial After Mounjaro, Zepbound Shortage Ends

Lee Brown with Third Bridge argues that demanding expectations are built into Eli Lilly's (LLY) stock following a "monstrous" 2Q earnings report. Mounjaro and Zepbound no longer on short supply helps the outlook, but Lee looks into other headwinds facing the pharmaceutical company, including the ILA Union's port worker strike.

Youtube | 1 year ago
Loading...
Load More